| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1015347916 |
| P356 | DOI | 10.1038/NBT.1869 |
| P8608 | Fatcat ID | release_7755swlehnedhlfwyrxwj332ra |
| P698 | PubMed publication ID | 21552233 |
| P2093 | author name string | Nafees N Malik | |
| P2860 | cites work | Coverage policy development for personalized medicine: private payer perspectives on developing policy for the 21-gene assay | Q34114888 |
| The Impact of CED On Private Payers. | Q36562846 | ||
| Access with evidence development: the US experience | Q39908685 | ||
| Personalized medicine: factors influencing reimbursement. | Q42698277 | ||
| Coverage options for promising technologies: Medicare's 'coverage with evidence development' | Q80244066 | ||
| Is personalized medicine finally arriving? | Q81236984 | ||
| A policy approach to the development of molecular diagnostic tests | Q82349672 | ||
| P433 | issue | 5 | |
| P304 | page(s) | 390-391 | |
| P577 | publication date | 2011-05-01 | |
| P1433 | published in | Nature Biotechnology | Q1893837 |
| P1476 | title | Overhauling the reimbursement system for molecular diagnostics. | |
| P478 | volume | 29 |
| Q84328069 | Biomarker patents for diagnostics: problem or solution? | cites work | P2860 |
Search more.